Martin Phillips
Directeur Général chez Opsidio LLC
Profil
Martin Phillips is currently the Chief Executive Officer & Director at Opsidio LLC since 2017.
Prior to this, he worked as the Senior Medical Director at Aventis Behring from 1997 to 2004.
He also held positions as Director at Context Therapeutics LLC, Chief Medical Officer & SVP-Clinical Development at Morphotek, Inc., and Chief Medical Officer at Millendo Therapeutics US, Inc. Additionally, he worked as an Associate Professor-Medicine at The University of Texas at Austin and as an Assistant Professor-Medicine at Baylor College of Medicine.
Dr. Phillips holds a doctorate degree from Wayne State University (Michigan) and an undergraduate degree from the University of Michigan.
Postes actifs de Martin Phillips
| Sociétés | Poste | Début |
|---|---|---|
Opsidio LLC
 Opsidio LLC Pharmaceuticals: MajorHealth Technology Opsidio LLC engages in developing monoclonal antibodies to treat fibrotic and remodeling diseases. The company is headquartered in Bryn Mawr, PA. | Directeur Général | 03/10/2017 |
Anciens postes connus de Martin Phillips
| Sociétés | Poste | Fin |
|---|---|---|
| Aventis Behring | Directeur Technique/Scientifique/R&D | - |
Context Therapeutics LLC
 Context Therapeutics LLC Pharmaceuticals: MajorHealth Technology Context Therapeutics LLC develops novel medicines for hormone responsive cancers. The company was founded by Martin Lehr in 2016 and is headquartered in Philadelphia, PA. | Directeur/Membre du Conseil | - |
Millendo Therapeutics US, Inc.
 Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Directeur Technique/Scientifique/R&D | - |
| The University of Texas at Austin | Corporate Officer/Principal | - |
| Baylor College of Medicine | Corporate Officer/Principal | - |
Formation de Martin Phillips
| Wayne State University (Michigan) | Doctorate Degree |
| University of Michigan | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Morphotek, Inc.
 Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | Commercial Services |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
| Aventis Behring | Health Technology |
Opsidio LLC
Opsidio LLC Pharmaceuticals: MajorHealth Technology Opsidio LLC engages in developing monoclonal antibodies to treat fibrotic and remodeling diseases. The company is headquartered in Bryn Mawr, PA. | Health Technology |
Context Therapeutics LLC
Context Therapeutics LLC Pharmaceuticals: MajorHealth Technology Context Therapeutics LLC develops novel medicines for hormone responsive cancers. The company was founded by Martin Lehr in 2016 and is headquartered in Philadelphia, PA. | Health Technology |
